The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 17, 2013
Filed:
May. 31, 2011
Menzo Jans Emco Havenga, Alphen aan den Rijn, NL;
Ronald Vogels, Linschoten, NL;
Jerald C. Sadoff, Bethesda, MD (US);
David Hone, Bethesda, MD (US);
Yasir Abdul Wahid Skeiky, Silver Spring, MD (US);
Katarina Rado{hacek Over (S)}evic, Rotterdam, NL;
Menzo Jans Emco Havenga, Alphen aan den Rijn, NL;
Ronald Vogels, Linschoten, NL;
Jerald C. Sadoff, Bethesda, MD (US);
David Hone, Bethesda, MD (US);
Yasir Abdul Wahid Skeiky, Silver Spring, MD (US);
Katarina Rado{hacek over (s)}evic, Rotterdam, NL;
Aeras Global TB Vaccine Foundation, Rockville, MD (US);
Crucell Holland B.V, Leiden, NL;
Abstract
The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.